Start Your Search
M. Pedraza Lorenzo
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
P1.01-060 - Nivolumab after Progression to Platinum- Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC) (ID 9214)
09:30 - 16:00 | Author(s): M. Pedraza Lorenzo
In patients with advanced non–small-cell lung cancer (NSCLC), docetaxel has been established as the second line of treatment after progression to platinum-based regimens. Following the results of the CheckMate 017 and 057 studies, Nivolumab, an anti-PD-1, has been second in line approved. This has increased overall survival in comparison with Docetaxel. This paper analyzes the experience with Nivolumab in second and successive lines of advanced NSCLC within the service of Medical Oncology from the Complejo Asistencial Universitario of León, Spain.
25 patients diagnosed with advanced NSCLC were included in the period from July 2015 to November 2016. The clinical-pathological characteristics, efficacy, objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and safety were analyzed. The dose of Nivolumab used was 3 mg/kg every 15 days.
The median age was 64 years old. All subjects had an ECOG performance status <2. 84% had stage IV cancer. 96% were current smokers or former smokers, in the same proportion (Table 1). 72% received a single pre-treatment line. A median of 7 cycles were administered (range: 2-28). The ORR was 28% (CR 4%, PR 24%) with a disease control rate of 44%. The median DOR was not reached at the time of analysis (range: 2.5+ - 10.4+ months). The median PFS was 5.4 months (95% CI 4.86-6). The rate of immune-related adverse events (IR-AE) of any grade was 36%, with endocrinopathies (hypothyroidism and hyperthyroidism) being the most common IR-AE (24%). The rate of IR-AE G3 was 8% (1 patient pneumonitis, 1 patient hepatotoxicity). There were no toxic deaths. Figure 1
Nivolumab represents a standard of treatment in advanced NSCLC. Its results of efficacy and safety in this retrospective real-time observational analysis (RWD), with 25 consecutive patients,are consistent with published studies. More patients and extended follow-up are required to draw more precise conclusions.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.